Your search for apixaban returned 100 results

Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery

Improved communication with patients about cost, bleeding, and monitoring may increase compliance

Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.

The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.

Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.

Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).

Older patients, females, and those with comorbidities were more likely to be on multiple medications.

Apixaban and rivaroxaban are both factor Xa inhibitors.